Yatsuga 2014.
Methods | A cohort study of methylphenidate use for 3 months | |
Participants | Number of participants screened: not stated Number of participants included:, 50 Number of participants followed up: 50 Number of withdrawals: 0 Diagnosis of ADHD: DSM‐IV TR (subtype not stated) Age: mean 9.7 years (SD 2 years 8 months) (range: 6‐16) IQ: mean 93.15 Sex: 50 males Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Japan Comorbidity: none Comedication: none Sociodemographics: not stated Inclusion criteria
Exclusion criteria
|
|
Interventions | Methylphenidate type: osmotic release oral system (OROS) Methylphenidate dosage: 18/27 mg (0.5‐1.2 mg/kg/day) Administration schedule: not stated Duration of intervention: 3 months Treatment compliance: not stated |
|
Outcomes |
Non‐serious adverse events: In all, 7 children reported some kind of adverse effect: 2 children reported headache, 3 children had appetite loss, 3 children had sleeplessness and 1 child reported appetite loss and sleeplessness |
|
Notes | Sample calculation: not stated
Ethics approval: ethics committee of Graduate School of Medical Sciences, Kumamoto University
Funding/vested interests/authors' affiliations: Grant‐in‐Aid for Scientific Research (B) and Challenging Exploratory Sports, Science and Technology (MEXT) of Japan (KAKENHI:grant number 24300149 and 23650223 to A.T). Partially supported by Grant in Aid for Scientific Research from Japan‐U.S. Brain Research Cooperation Program (grant number 210201 to A.T) as well as the Research Grants from the University of Fukui to AT. The funding organisations had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or in preparation, review or approval of the manuscript. No authors have financial or personal relations that could pose a conflict of interest
Any withdrawals due to adverse events: none Key conclusions of the study authors: this study showed no relation between the COMT genotype and methylphenidate adverse effects Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: none indicated |